840501-15-7

Basic information

• Product Name: Benzenemethanol, 4-amino-2-fluoro- (9CI)
• Synonyms: Benzenemethanol, 4-amino-2-fluoro- (9CI);(4-aMino-2-fluorophenyl)Methanol
• CAS NO: 840501-15-7
• Molecular Formula: C₇H₈FNO
• Molecular Weight: 141.1429232
• Product Categories: VARIOUSAMINE
• Mol File: 840501-15-7.mol

Chemical Properties

• Boiling Point: 286.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.286±0.06 g/cm3(Predicted)
• PKA: 13.88±0.10(Predicted)
• CAS DataBase Reference: Benzenemethanol, 4-amino-2-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 4-amino-2-fluoro- (9CI)(840501-15-7)
• EPA Substance Registry System: Benzenemethanol, 4-amino-2-fluoro- (9CI)(840501-15-7)

Safety Data

• Hazardous Substances Data: 840501-15-7(Hazardous Substances Data)

Usage

Chemical compound

Benzenemethanol, 4-amino-2-fluoro(9CI)

Chemical Abstracts Service (CAS) registry number

115799-50-9
Derivative of benzenemethanol with a fluoro substitution
Potential applications in pharmaceutical and chemical industries
Can be used as a building block in the synthesis of organic compounds
Subject of interest for researchers and manufacturers in organic chemistry and drug development industries

Upstream product

• 73792-08-2 methyl 4-amino-2-fluorobenzoate 
• 1427-07-2 2-fluoro-4-nitrotoluene 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 392-09-6 2-fluoro-4-nitro-benzoic acid methyl ester 
• 660432-43-9 (2-fluoro-4-nitrophenyl)methanol 
• 446-31-1 2-fluoro-4-aminobenzoic acid 

Downstream Products

• 1402585-34-5 C₁₃H₁₂F₄N₄O₂ 
• 1402581-32-1 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]-methyl]-3-[3-fluoro-4-(hydroxymethyl)-phenyl]-urea 
• 1402581-33-2 1-[[2-(4-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methyl]-3-[3-fluoro-4-(hydroxymethyl)phenyl]urea 
• 1402581-34-3 1-[[2-(2,3-dichlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methyl]-3-[3-fluoro-4-(hydroxymethyl)phenyl]urea 
• 1402581-35-4 1-[[2-(3-chloro-2-methoxyphenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methyl]-3-[3-fluoro-4-(hydroxymethyl)phenyl]urea 
• 1402581-36-5 1-[[2-(5-chloro-2-methoxyphenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methyl]-3-[3-fluoro-4-(hydroxymethyl)phenyl]urea 
• 1402582-07-3 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(3-fluoro-4-formylphenyl)urea 
• 1402585-33-4 phenyl (3-fluoro-4-(hydroxymethyl)phenyl)carbamate 
• 1413913-01-5 2-cyano-3-(2-fluoro-4-(7-pivaloyl-5H-pyrrolo[2,3-b]pyrazin-2-ylamino)phenyl)-N,N-dimethylacrylamide 
• 1413913-13-9 2-cyano-3-(2-fluoro-4-(7-pivaloyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazin-2-ylamino)-phenyl)-N,N-dimethylacrylamide 
• 1413913-08-2 2-fluoro-4-(7-pivaloyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazin-2-ylamino)benzaldehyde 
• 1413913-06-0 1-(2-(3-fluoro-4-(hydroxymethyl)phenylamino)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo [2,3-b]pyrazin-7-yl)-2,2-dimethylpropan-1-one 
• 840501-17-9 [4-(tert-butyl-dimethyl-silanyloxymethyl)-3-fluoro-phenyl]-carbamic acid benzyl ester 

Relevant articles and documents

Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic

Paradoxically, some TRPV1 agonists are, at the organismal level, both nonpungent and clinically useful as topical analgesics. Here, we describe the scaled-up synthesis and characterization in mouse models of a novel, nonpungent vanilloid. Potent analgesic activity was observed in models of neuropathic pain, and the compound blocked capsaicin induced allodynia, showing dermal accumulation with little transdermal absorption. Finally, it displayed much weaker systemic toxicity compared to capsaicin and was negative in assays of genotoxicity.

Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain

In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting.

Mechanistic Evaluation of Bioorthogonal Decaging with trans-Cyclooctene: The Effect of Fluorine Substituents on Aryl Azide Reactivity and Decaging from the 1,2,3-Triazoline

Bioorthogonal prodrug activation/decaging strategies need to be selective, rapid and release the drug from the masking group upon activation. The rates of the 1,3-dipolar cycloaddition between a trans-cyclooctene (TCO) and a series of fluorine-substituted

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (Q) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH A CO-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a CO-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

Effects of positional and geometrical isomerism on the biological activity of some novel oxazolidinones

Some novel oxazolidinone derivatives have been synthesized and tested for antibacterial activity. Compound 13 was found to be active against Gram-positive pathogens whereas compound 14 was less active. Either less active or inactive molecules were obtained, when benzotriazole was replaced with benzimidazole, benzthiazole, or benzoxazole. However, thioacetamide analogue of 13 produced a potent molecule similar to linezolid in vitro. Some novel oxazolidinone derivatives with benzotriazole as pendant have been synthesized and tested for antibacterial activity. Linearly attached benzotriazole derivative showed more potency compared to angular one in vitro. Out of E/Z-isomers of angularly attached derivatives E-isomer was found to be more potent than Z-isomer. Either less active or inactive molecules were obtained, when benzotriazole was replaced with benzimidazole, benzthiazole, or benzoxazole. Finally, thioacetamide analogue of linear compound gave a lead having activity similar to linezolid in vitro.